8 results on '"Czernin, Johannes"'
Search Results
2. Comparison of PSMA-TO-1 and PSMA-617 labeled with gallium-68, lutetium-177 and actinium-225
- Author
-
Meyer, Catherine, Prasad, Vikas, Stuparu, Andreea, Kletting, Peter, Glatting, Gerhard, Miksch, Jonathan, Solbach, Christoph, Lueckerath, Katharina, Nyiranshuti, Lea, Zhu, Shaojun, Czernin, Johannes, Beer, Ambros J, Slavik, Roger, Calais, Jeremie, and Dahlbom, Magnus
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Urologic Diseases ,Prostate Cancer ,Biomedical Imaging ,Cancer ,PSMA-TO-1 ,PSMA-617 ,Prostate cancer ,Radioligand therapy ,Dosimetry ,Medical Biochemistry and Metabolomics ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundPSMA-TO-1 ("Tumor-Optimized-1") is a novel PSMA ligand with longer circulation time than PSMA-617. We compared the biodistribution in subcutaneous tumor-bearing mice of PSMA-TO-1, PSMA-617 and PSMA-11 when labeled with 68Ga and 177Lu, and the survival after treatment with 225Ac-PSMA-TO-1/-617 in a murine model of disseminated prostate cancer. We also report dosimetry data of 177Lu-PSMA-TO1/-617 in prostate cancer patients.MethodsFirst, PET images of 68Ga-PSMA-TO-1/-617/-11 were acquired on consecutive days in three mice bearing subcutaneous C4-2 xenografts. Second, 50 subcutaneous tumor-bearing mice received either 30 MBq of 177Lu-PSMA-617 or 177Lu-PSMA-TO-1 and were sacrificed at 1, 4, 24, 48 and 168 h for ex vivo gamma counting and biodistribution. Third, mice bearing disseminated lesions via intracardiac inoculation were treated with either 40 kBq of 225Ac-PSMA-617, 225Ac-PSMA-TO-1, or remained untreated and followed for survival. Additionally, 3 metastatic castration-resistant prostate cancer patients received 500 MBq of 177Lu-PSMA-TO-1 under compassionate use for dosimetry purposes. Planar images with an additional SPECT/CT acquisition were acquired for dosimetry calculations.ResultsTumor uptake measured by PET imaging of 68Ga-labeled agents in mice was highest using PSMA-617, followed by PSMA-TO-1 and PSMA-11. 177Lu-PSMA tumor uptake measured by ex vivo gamma counting at subsequent time points tended to be greater for PSMA-TO-1 up to 1 week following treatment (p > 0.13 at all time points). This was, however, accompanied by increased kidney uptake and a 26-fold higher kidney dose of PSMA-TO-1 compared with PSMA-617 in mice. Mice treated with a single-cycle 225Ac-PSMA-TO-1 survived longer than those treated with 225Ac-PSMA-617 and untreated mice, respectively (17.8, 14.5 and 7.7 weeks, respectively; p
- Published
- 2022
3. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial
- Author
-
Polverari, Giulia, Ceci, Francesco, Passera, Roberto, Crane, Jacquelyn, Du, Lin, Li, Gang, Fanti, Stefano, Bernthal, Nicholas, Eilber, Fritz C, Allen-Auerbach, Martin, Czernin, Johannes, Calais, Jeremie, and Federman, Noah
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Trials and Supportive Activities ,Rare Diseases ,Pediatric ,Pediatric Research Initiative ,Pediatric Cancer ,Prevention ,Biomedical Imaging ,Clinical Research ,Cancer ,Detection ,screening and diagnosis ,4.2 Evaluation of markers and technologies ,[F-18]FDG ,PET ,CT ,Sarcoma ,Neoadjuvant chemotherapy ,Therapy response ,Pediatrics ,PET/CT ,[18F]FDG ,Medical Biochemistry and Metabolomics ,Clinical sciences ,Oncology and carcinogenesis - Abstract
IntroductionThis is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [18F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX).MethodsBone or soft tissue sarcoma patients with (1) baseline [18F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only.ResultsThirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p
- Published
- 2020
4. Preclinical evaluation of PSMA expression in response to androgen receptor blockade for theranostics in prostate cancer
- Author
-
Lückerath, Katharina, Wei, Liu, Fendler, Wolfgang P, Evans-Axelsson, Susan, Stuparu, Andreea D, Slavik, Roger, Mona, Christine E, Calais, Jeremie, Rettig, Matthew, Reiter, Robert E, Herrmann, Ken, Radu, Caius G, Czernin, Johannes, and Eiber, Matthias
- Subjects
Biomedical and Clinical Sciences ,Clinical Sciences ,Oncology and Carcinogenesis ,Clinical Research ,Aging ,Urologic Diseases ,Clinical Trials and Supportive Activities ,Biomedical Imaging ,Prostate Cancer ,Radiation Oncology ,Cancer ,5.1 Pharmaceuticals ,PSMA ,Prostate cancer ,Ga-68-PSMA PET ,CT ,Androgen receptor blockade ,Radioligand therapy ,68Ga-PSMA PET/CT ,Medical Biochemistry and Metabolomics ,Clinical sciences ,Oncology and carcinogenesis - Abstract
BackgroundProstate-specific membrane antigen (PSMA)-directed radioligand therapy (RLT) is a promising yet not curative approach in castration-resistant (CR) prostate cancer (PC). Rational combination therapies may improve treatment efficacy. Here, we explored the effect of androgen receptor blockade (ARB) on PSMA expression visualized by PET and its potential additive effect when combined with 177Lu-PSMA RLT in a mouse model of prostate cancer.MethodsMice bearing human CRPC (C4-2 cells) xenografts were treated with 10 mg/kg enzalutamide (ENZ), with 50 mg/kg bicalutamide (BIC), or vehicle (control) for 21 days. PSMA expression was evaluated by 68Ga-PSMA11 PET/CT and quantified by flow cytometry of tumor fine needle aspirations before treatment and on days 23, 29, 34, and 39 post-therapy induction. For the RLT combination approach, mice bearing C4-2 tumors were treated with 10 mg/kg ENZ or vehicle for 21 days before receiving either 15 MBq (84 GBq/μmol) 177Lu-PSMA617 or vehicle. DNA damage was assessed as phospho-γH2A.X foci in tumor biopsies. Reduction of tumor volume on CT and survival were used as study endpoints.ResultsTumor growth was delayed by ARB while 68Ga-PSMA11 uptake increased up to 2.3-fold over time when compared to controls. ABR-induced upregulation of PSMA expression was confirmed by flow cytometry. Phospho-γH2A.X levels increased 1.8- and 3.4-fold at 48 h in response to single treatment ENZ or RLT and ENZ+RLT, respectively. Despite significantly greater DNA damage and persistent increase of PSMA expression at the time of RLT, no additional tumor growth retardation was observed in the ENZ+RLT group (vs. RLT only, p = 0.372 at day 81). Median survival did not improve significantly when ENZ was combined with RLT.ConclusionARB-mediated increases in PSMA expression in PC xenografts were evident by 68Ga-PSMA11 PET imaging and flow cytometry. 177Lu-PSMA617 effectively decreased C4-2 tumor size. However, while pre-treatment with ARB increased DNA damage significantly, it did not result in synergistic effects when combined with RLT.
- Published
- 2018
5. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis
- Author
-
Gafita, Andrei, Calais, Jeremie, Franz, Charlott, Rauscher, Isabel, Wang, Hui, Roberstson, Andrew, Czernin, Johannes, Weber, Wolfgang A., and Eiber, Matthias
- Published
- 2019
- Full Text
- View/download PDF
6. [18F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.
- Author
-
Polverari, Giulia, Ceci, Francesco, Passera, Roberto, Crane, Jacquelyn, Du, Lin, Li, Gang, Fanti, Stefano, Bernthal, Nicholas, Eilber, Fritz C., Allen-Auerbach, Martin, Czernin, Johannes, Calais, Jeremie, and Federman, Noah
- Subjects
EWING'S sarcoma ,POSITRON emission tomography computed tomography ,SYNOVIOMA ,SARCOMA ,BONES ,CANCER chemotherapy - Abstract
Introduction: This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [
18 F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX). Methods: Bone or soft tissue sarcoma patients with (1) baseline [18 F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18 F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18 F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only. Results: Thirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16–84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p < 0.02). ΔMTV was associated with tissue response to neo-CTX (p = 0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS. Conclusion: [18 F]FDG PET/CT performed 6 weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. Evaluation of SUV normalized by lean body mass (SUL) in 68Ga-PSMA11 PET/CT: a bi-centric analysis.
- Author
-
Gafita, Andrei, Calais, Jeremie, Franz, Charlott, Rauscher, Isabel, Wang, Hui, Roberstson, Andrew, Czernin, Johannes, Weber, Wolfgang A., and Eiber, Matthias
- Subjects
LEAN body mass ,DUAL-energy X-ray absorptiometry ,BODY weight ,PROSTATE cancer patients - Abstract
Introduction: The aim of this analysis was to investigate whether the standardized uptake value (SUV) normalized by lean body mass (SUL) is a more appropriate quantitative parameter compared to the commonly used SUV normalized by patient's weight in
68 Ga-PSMA11 PET/CT. Material and methods:68 Ga-PSMA11 PET/CT scans of 121 patients with prostate cancer from two institutions were evaluated. Liver SUV was measured within a 3-cm volume-of-interest (VOI) in the right hepatic lobe and corrected for lean body mass using the Janmahasatian formula. SUV and SUL repeatability between baseline and follow-up scans of the same patients were assessed. Results: SUV was significantly positively correlated with body weight (r = 0.35, p = 0.02). In contrast, SUL was not correlated with body weight (r = 0.23, p = 0.07). No significant differences were found between baseline and follow-up scan (p = 0.52). Conclusion: The Janmahasatian formula annuls the positive correlations between SUV and body weight, suggesting that SUL is preferable to SUV for quantitative analyses of68 Ga-PSMA11 PET/CT scans. [ABSTRACT FROM AUTHOR]- Published
- 2019
- Full Text
- View/download PDF
8. [ 18 F]FDG PET/CT for evaluating early response to neoadjuvant chemotherapy in pediatric patients with sarcoma: a prospective single-center trial.
- Author
-
Polverari G, Ceci F, Passera R, Crane J, Du L, Li G, Fanti S, Bernthal N, Eilber FC, Allen-Auerbach M, Czernin J, Calais J, and Federman N
- Abstract
Introduction: This is a prospective, single-center trial in pediatric patients with sarcoma aiming to evaluate [
18 F]FDG PET/CT as a tool for early response assessment to neoadjuvant chemotherapy (neo-CTX)., Methods: Bone or soft tissue sarcoma patients with (1) baseline [18 F]FDG PET/CT within 4 weeks prior to the start of neo-CTX (PET1), (2) early interim [18 F]FDG PET/CT (6 weeks after the start of neo-CTX (PET2), (3) evaluation of neo-CTX response by histology or MRI, and (4) definitive therapy after neo-CTX (surgery or radiation) were included. Semiquantitative PET parameters (SUVmax, SUVmean, SUVpeak, MTV and TLG) and their changes from PET1 to PET2 (ΔPET) were obtained. The primary endpoint was to evaluate the predictive value of PET1, PET2 and ΔPET parameters for overall survival (OS) and time to progression (TTP). The secondary outcome was to evaluate if [18 F]FDG PET/CT can predict the response to neo-CTX assessed by histopathology or MRI. Primary and secondary outcomes were also evaluated in a subpopulation of patients with bone involvement only., Results: Thirty-four consecutive patients were enrolled (10 females; 24 males; median age 15.1 years). 17/34 patients (50%) had osteosarcoma, 13/34 (38%) Ewing's sarcoma, 2/34 (6%) synovial sarcoma and 2/34 (6%) embryonal liver sarcoma. Median follow-up was 39 months (range 16-84). Eight of 34 patients (24%) died, 9/34 (27%) were alive with disease, and 17/34 (50%) had no evidence of residual/recurrent disease. Fifteen of 34 (44%) and 19/34 (56%) were responders and non-responders, respectively. PET2-parameters were associated with longer TTP (p < 0.02). ΔMTV was associated with tissue response to neo-CTX (p = 0.047). None of the PET1, PET2 or ΔPET parameters were associated with OS., Conclusion: [18 F]FDG PET/CT performed 6 weeks after the start of neo-CTX can serve as an early interim biomarker for TTP and pathologic response but not for OS in pediatric patients with sarcoma.- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.